Evaluation of Hyperammonemia and Cognitive Impairment in post-COVID patients
D. D. Mukhametova,
E. N. Belousova,
Z. I. Fashieva,
M. G. Nazarova,
M. V. Knyazeva,
D. I. Abdulganieva https://doi.org/10.31146/1682-8658-ecg-216-8-66-72
Abstract
The paper presents the results of an assessment cognitive function and ammonium levels in individuals who have had a novel coronavirus infection (COVID-19). The study included 60 people: 41 - confirmed COVID-19 during last 3 months and 19 - the control group. There have been performed clinical examination, psychometric test - connect-the-numbers test (CNT) and Mini-Mental State Examination (MMSE). Blood ammonium level has been determined. Post-COVID-19 syndrome (PCS) was diagnosed in 70.7% of patients, which was manifested by complaints of memory loss, weakness and anxiety. In patients who underwent COVID-19, cognitive impairment was detected on the MMSE scale in 27 people (45%), and the changes were more pronounced in the group with PCS. In the post-COVID group, 66% of the subjects had an increase CNT result. The cognitive impairment according to the MMSE correlated with the CNT results. Hyperammonemia was found in 54% of COVID-19 survivors, with higher values observed in the PCS group. No correlation was found between hyperammonemia and cognitive impairment.
About the Authors
D. D. Mukhametova
Kazan State Medical University
Russian Federation
Russian Federation
E. N. Belousova
Kazan State Medical University
Russian Federation
Russian Federation
Z. I. Fashieva
Kazan State Medical University
Russian Federation
Russian Federation
M. G. Nazarova
Kazan State Medical University
Russian Federation
Russian Federation
M. V. Knyazeva
Kazan State Medical University
Russian Federation
Russian Federation
D. I. Abdulganieva
Kazan State Medical University
Russian Federation
Russian Federation
References
1. Interim guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)”, Version 16. approved. Ministry of Health of Russia 18.08.2022. (in Russ.) Available at: https://edu.rosminzdrav.ru/anonsy/anonsy/news/vremennye-metodicheskie-rekomendacii-profilaktika-d/(Access 01.11.2022.)@@ Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)», Версия 16. утв. Минздравом России 18.08.2022.
2. Soriano J.B., Allan M., Alsokhn C., et al. A clinical case definition of post COVID-19 condition by a Delphi consensus. October 6 2021. Available at: https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf?sequence=1&isAllowed=y (Access 01.11.2022.)
3. Bogolepova A.N., Osinovskaya N. A., Kovalenko E. A., Makhnovich E. V. Fatigue and cognitive impairment in post-COVID syndrome: possible treatment approaches. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):88-93. (In Russ.) doi: 10.14412/2074-2711-2021-4-88-93.@@ Боголепова А. Н., Осиновская Н. А., Коваленко Е. А., Махнович Е. В. Возможные подходы к терапии астенических и когнитивных нарушений при постковидном синдроме. Неврология, нейропсихиатрия, психосоматика. 2021;13(4):88-93. doi: 10.14412/2074-2711-2021-4-88-93.
4. Ostroumova T.M., Chernousov P. A., Kuznetsov I. V. Cognitive impairment in COVID-19 survivors. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):126-130. (In Russ.) doi: 10.14412/2074-2711-2021-1-126-130.@@ Остроумова Т. М., Черноусов П. А., Кузнецов И. В. Когнитивные нарушения у пациентов, перенесших COVID-19. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):126-130. doi: 10.14412/2074-2711-2021-1-126-130.
5. Golovacheva V.A., Tabeeva G. R., Kuznetsov I. V. Cognitive impairment in COVID-19: associations, pathogenesis and treatment questions. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(2):123-129. (In Russ.) doi: 10.14412/2074-2711-2021-2-123-129.@@ Головачева В. А., Табеева Г. Р., Кузнецов И. В. Когнитивные нарушения при COVID-19: взаимосвязь, патогенез и вопросы терапии. Неврология, нейропсихиатрия, психосоматика. 2021;13(2):123-129. doi: 10.14412/2074-2711-2021-2-123-129.
6. Marjot T., Webb G. J., Barritt A.S 4th., Moon A. M., Stamataki Z., Wong V. W., Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021 May;18(5):348-364. doi: 10.1038/s41575-021-00426-4.
7. Lazebnik L.B., Tarasova L. V., Komarova E. A., et al. Change in concentration of ammonia and other biochemical indicators in patients with new coronaviral infection. Experimental and Clinical Gastroenterology. 2021;(4):76-83. (In Russ.) doi: 10.31146/1682-8658-ecg-188-4-76-83.@@ Лазебник Л. Б., Тарасова Л. В., Комарова Е. А. и соавт. Изменение концентрации аммиака и других биохимических показателей у пациентов с новой коронавирусной инфекцией. Экспериментальная и клиническая гастроэнтерология. 2021;(4):76-83. doi: 10.31146/1682-8658-ecg-188-4-76-83.
8. Lazebnik L.B., Golovanova E. V., Alekseenko S. A., et al.Russian Consensus “Hyperammonemia in Adults” (Version 2021). Experimental and Clinical Gastroenterology. 2021;(3):97-118. (In Russ.) doi: 10.31146/1682-8658-ecg-187-3-97-118.@@ Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и соавт. Российский консенсус «Гипераммониемии у взрослых» (Версия 2021). Экспериментальная и клиническая гастроэнтерология. 2021;(3):97-118. doi: 10.31146/1682-8658-ecg-187-3-97-118.
9. [Atlas for experimental study of deviations in human mental activity]. Edd. I. A. Polishchuk, A. E. Vidrenko. 2nd ed. Kyiv, Health Publ., 1979. 124 p.; insert 32 p. (In Russ.)@@ Атлас для экспериментального исследования отклонений в психической деятельности человека. Под ред. И. А. Полищука, А. Е. Видренко. 2-е изд., перераб. и доп. Киев, «Здоров’я», 1979. 124 с; вкладка 32 с.
10. [Instructions for using the portable express analyzer PocketChemBAPA-4140]. (In Russ.) Available at: https://www.ecomeds.ru/item_1508.htm (Access 01.11.2022.)@@ Инструкция по использованию портативного экспресс анализатора PocketChemBAPA-4140. URL: https://www.ecomeds.ru/item_1508.htm (Дата обращения: 01.11.2022)
11. Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8.
12. Hadad R., Khoury J., Stanger C., et al. Cognitive dysfunction following COVID-19 infection. J Neurovirol. 2022 Jun;28(3):430-437. doi: 10.1007/s13365-022-01079-y.
13. Rudroff T., Workman C. D., Bryant A. D. Potential Factors That Contribute to Post-COVID-19 Fatigue in Women. Brain Sci. 2022 Apr 26;12(5):556. doi: 10.3390/brainsci12050556.
14. Negrini F., Ferrario I., Mazziotti D., et al. Neuropsychological Features of Severe Hospitalized Coronavirus Disease 2019 Patients at Clinical Stability and Clues for Postacute Rehabilitation. Arch Phys Med Rehabil. 2021 Jan;102(1):155-158. doi: 10.1016/j.apmr.2020.09.376.
15. Sommer I.E., Bakker P. R. What can psychiatrists learn from SARS and MERS outbreaks? Lancet Psychiatry. 2020 Jul;7(7):565-566. doi: 10.1016/S2215-0366(20)30219-4.
16. Tomasoni D., Bai F., Castoldi R., et al. Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy. J Med Virol. 2021 Feb;93(2):1175-1179. doi: 10.1002/jmv.26459.
17. Mosolov S. N. Long-term psychiatric sequelae of SARS8CoV82 infection. Sovrem. ter. psih. rasstrojstv = Current Therapy of Mental Disorders. 2021;3:2-23. (In Russ.) doi: 10.21265/PSYPH.2021.31.25.001.@@ Мосолов С. Н. Длительные психические нарушения после перенесенной острой коронавирусной инфекции SARS-CoV-2. Современная терапия психических расстройств. 2021;3:2-23. doi: 10.21265/PSYPH.2021.31.25.001.
18. Zhang C., Shi L., Wang F. S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1.
Review
For citations:
Mukhametova D.D., Belousova E.N., Fashieva Z.I., Nazarova M.G., Knyazeva M.V., Abdulganieva D.I. Evaluation of Hyperammonemia and Cognitive Impairment in post-COVID patients. Experimental and Clinical Gastroenterology. 2023;(8):66-72. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-216-8-66-72
Views:
340
Email this article 